These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37350410)

  • 1. NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia.
    Wang X; Rong S; Sun Y; Yin B; Yang X; Lu X; Sun H; Yan Y; Sun G; Liang Y; Wang P; Xie S; Li Y
    Oncol Rep; 2023 Aug; 50(2):. PubMed ID: 37350410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
    Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
    Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
    Han Y; Ma Z
    Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
    Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
    Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia.
    Cao HX; Miao CF; Sang LN; Huang YM; Zhang R; Sun L; Jiang ZX
    Life Sci; 2020 Feb; 243():117255. PubMed ID: 31923418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
    Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
    Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
    J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia.
    Liu YY; Jiao WY; Li T; Bao YY
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8468-8475. PubMed ID: 31646577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
    Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of
    Deng Y; Li X; Feng J; Zhang X
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p.
    Pan D; Yang W; Zeng Y; Li W; Wang K; Zhao L; Li J; Ye Y; Guo Q
    Cell Signal; 2021 Aug; 84():110038. PubMed ID: 33984486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-199a-3p Overexpression Suppressed Cell Proliferation and Sensitized Chronic Myeloid Leukaemia Cells to Imatinib by Inhibiting mTOR Signalling.
    Liu X; Cui MM; Zhu HZ; Fu PY; Wang GC; Huang L
    Acta Haematol; 2022; 145(5):484-498. PubMed ID: 35313299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB.
    Zhu X; Zhang J; Sun Y; Wang Y; Liu Q; Li P; Yu S; Liu N; Ye J; Ma D; Ji C
    Bioengineered; 2022 Apr; 13(4):8881-8892. PubMed ID: 35333695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
    Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-577 promotes the sensitivity of chronic myeloid leukemia cells to imatinib by targeting NUP160.
    Zhang XT; Dong SH; Zhang JY; Shan B
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):7008-7015. PubMed ID: 31486501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY; Sun GB; Wang YJ; Yan F
    Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.